miR-224-5p-enriched exosomes promote tumorigenesis by directly targeting androgen receptor in non-small cell lung cancer.
AR
Exosome
NSCLC
Tumorigenesis
miR-224-5p
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
05 Mar 2021
05 Mar 2021
Historique:
received:
18
06
2020
accepted:
24
01
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
Non-small cell lung cancer (NSCLC) is the most common form of cancer, resulting in cancer-related deaths worldwide. Exosomes, a subclass of extracellular vesicles, are produced and secreted from various types of cells, including cancer cells. Cancer-derived exosomes can deliver nucleic acids, proteins, and lipids to provide a favorable microenvironment that supports tumor growth through enhancing cell proliferation and metastasis. Our results showed that miR-224-5p was upregulated in NSCLC patient tissues and cell lines, with a tumor-promoting phenotype. Meanwhile, exosome-derived miR-224-5p induced cell proliferation and metastasis in NSCLC and human lung cells. Moreover, we characterized the androgen receptor (AR) as a direct target of miR-224-5p. Tumor xenograft assay experiments revealed that overexpression of miR-224-5p drove NSCLC tumor growth via the suppression of AR and the mediation of epithelial-mesenchymal transition (EMT). Collectively, our results suggest that miR-224-5p-enriched exosomes promote tumorigenesis by directly targeting AR in NSCLC, which may provide novel potential therapeutic and preventive targets for NSCLC.
Identifiants
pubmed: 33664999
doi: 10.1016/j.omtn.2021.01.028
pii: S2162-2531(21)00028-7
pmc: PMC7899953
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1217-1228Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Oncogene. 2019 Jul;38(28):5700-5724
pubmed: 31043708
Sci Rep. 2015 Jun 22;5:11392
pubmed: 26096604
Cell Death Dis. 2017 May 4;8(5):e2764
pubmed: 28471447
Prog Lipid Res. 2017 Apr;66:30-41
pubmed: 28342835
Cancer Cell. 2014 Nov 10;26(5):707-21
pubmed: 25446899
Nat Commun. 2017 Apr 10;8:15016
pubmed: 28393839
J Natl Cancer Inst. 2018 Jul 1;110(7):734-742
pubmed: 29346580
Int J Biol Sci. 2019 Apr 22;15(5):1072-1079
pubmed: 31182926
Cancer. 2012 Jan 1;118(1):157-63
pubmed: 21713768
J Natl Cancer Inst. 2019 Jul 1;111(7):700-708
pubmed: 30445651
Pharmacol Ther. 2017 Jun;174:63-78
pubmed: 28202367
Biomed Pharmacother. 2019 Mar;111:1103-1111
pubmed: 30841423
Semin Oncol. 2009 Dec;36(6):572-80
pubmed: 19995649
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Nat Commun. 2018 Jan 15;9(1):191
pubmed: 29335551
Nat Commun. 2018 Dec 19;9(1):5395
pubmed: 30568162
Mol Cancer. 2018 Apr 20;17(1):82
pubmed: 29678180
J Thorac Oncol. 2017 Jul;12(7):1098-1108
pubmed: 28461256
Mol Cancer Res. 2018 Feb;16(2):233-242
pubmed: 29117942
Nat Rev Cancer. 2014 Aug;14(8):535-46
pubmed: 25056707
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Stem Cells. 2017 May;35(5):1208-1221
pubmed: 28090688
Cold Spring Harb Perspect Med. 2017 Sep 1;7(9):
pubmed: 28389515
J Transl Med. 2019 Sep 11;17(1):308
pubmed: 31511014
Steroids. 2016 Sep;113:5-13
pubmed: 27234503
Horm Cancer. 2015 Jun;6(2-3):120-7
pubmed: 25792547
Cancer Res. 2017 Dec 1;77(23):6480-6488
pubmed: 29162616
World J Gastroenterol. 2019 Apr 21;25(15):1890-1898
pubmed: 31057302
Mol Cancer. 2019 Mar 19;18(1):43
pubmed: 30890168
J Cancer. 2019 Jun 2;10(11):2472-2479
pubmed: 31258753
Acta Oncol. 2015 Mar;54(3):333-9
pubmed: 25291077
Genome Biol. 2019 Jan 14;20(1):12
pubmed: 30642385
Cancer Cell. 2016 May 9;29(5):653-668
pubmed: 27117758
Cancer Treat Rev. 2018 Jul;68:102-110
pubmed: 29940524
Oncotarget. 2016 Dec 13;7(50):82648-82657
pubmed: 27690341
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancers (Basel). 2017 Feb 22;9(2):
pubmed: 28241422
Oncogene. 2017 Feb 2;36(5):639-651
pubmed: 27345402
Oncol Lett. 2018 May;15(5):7069-7075
pubmed: 29731873
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4288-97
pubmed: 26187928
JAMA Oncol. 2017 Sep 01;3(9):1266-1273
pubmed: 28301631